Asset Details
Do you wish to reserve the book?
Harnessing random peptide mixtures to combat multidrug-resistant fungal infections
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Harnessing random peptide mixtures to combat multidrug-resistant fungal infections
Do you wish to request the book?
Harnessing random peptide mixtures to combat multidrug-resistant fungal infections
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Harnessing random peptide mixtures to combat multidrug-resistant fungal infections
2026
Overview
The rising prevalence of invasive fungal infections, particularly among immunocompromised individuals, has become a critical public health concern. However, antifungal drug development has not kept pace with this growing need, and treatment options remain limited to a small number of drug classes. The emergence of multidrug-resistant fungal pathogens, such as Candida auris , further exacerbates this crisis by reducing the efficacy of existing therapeutics and increasing the risk of treatment failure. In this study, we evaluate the antifungal potential of FK20, a random peptide mixture (RPM) composed of L-phenylalanine and L-lysine. FK20 displays potent activity against C. auris and other clinically relevant Candida species, impairs biofilm formation, and exhibits synergy with caspofungin. Importantly, FK20 limits the emergence of resistance and demonstrates therapeutic efficacy in a murine model of systemic candidiasis. These findings establish RPMs as a promising new class of antifungals with broad-spectrum activity and clinical potential against drug-resistant fungal infections.
Publisher
American Society for Microbiology,American Society for Microbiology (ASM)
Subject
/ AMR
/ Animals
/ Antifungal Agents - chemical synthesis
/ Antifungal Agents - pharmacology
/ Antifungal Agents - therapeutic use
/ Antifungal Resistance in Pathogenesis
/ Antimicrobial Peptides - pharmacology
/ Aspergillus fumigatus - drug effects
/ Candida auris - drug effects
/ Clinical Microbiology and Infectious Diseases
/ Cryptococcus neoformans - drug effects
/ Drug Resistance, Multiple, Fungal - drug effects
/ Female
/ Humans
/ Mice
/ Microbial Pathogenesis and Immunology
/ Mycology
